In May 2014, Hélène Théophile and a team of researchers published an article titled “Five cases of sprue-like enteropathy in patients treated by olmesartan,” which further demonstrated that exposure to Benicar (olmesartan) is linked to an increased risk for severe gastrointestinal disease.
Here is the abstract for that article:
“We describe five cases of sprue-like enteropathy during treatment with olmesartan, [a drug] indicated for the treatment of hypertension. Patients presented severe diarrhoea, significant weight loss or dehydration, with or without intestinal villous atrophy. Clinical signs ceased upon drug discontinuation in all cases; olmesartan was reintroduced in two cases and rechallenge was positive in both. These add to the previously reported cases that led to a label change for olmesartan in the United States. However, all cases were observed in a small gastroenterology unit, which suggests that this adverse effect may not be rare. A preliminary search for the other angiotensin II receptor antagonists in the French pharmacovigilance system found severe diarrhoea and colitis, but no case with villous atrophy. Therefore, in the presence of severe diarrhoea, olmesartan or other angiotensin II receptor antagonists should be discontinued, even if the treatment has been taken for several months or years.” (emphasis added)
Due to the fact that the manufacturer of Benicar has failed time and again to adequately inform users of these and other serious risks, a number of Benicar lawsuits are currently being filed. If you or a loved one used Benicar and suffered gastrointestinal disease, you too may be entitled to significant financial compensation.
For a free, no-obligation case consultation, contact our team of Benicar lawyers at the information provided below. We have the experience, resources, and skills required to win the justice you deserve.
(855) 452 – 5529
Call today and see how we can help.